HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahrén, B. Articles by Mari, A. Search for Related Content PubMed PubMed Citation Articles by Ahrén, B. Articles by Mari, A. Social Bookmarking                What's this?

Characterization of GLP-1 Effects on ß-Cell Function After Meal Ingestion in Humans

¹ Department of Medicine, Lund University, Lund, Sweden
² Department of Medical Physiology, the Panum Institute, Copenhagen University, Copenhagen, Denmark
³ Institute of Biomedical Engineering, National Research Council, Padua, Italy

Address correspondence and reprint requests to Dr. Bo Ahrén, Department of Medicine, B11 BMC, SE-221 84 Lund, Sweden. E-mail: bo.ahren{at}med.lu.se

OBJECTIVE—Glucagon-like peptide 1 (GLP-1) is an incretin that augments insulin secretion after meal intake and is developed for treatment of type 2 diabetes. As a novel therapeutic agent, characteristics of its ß-cell effects are important to establish. Previously, ß-cell effects of GLP-1 have been characterized in humans during graded intravenous infusions of glucose, whereas its effects after more physiological stimuli, like meal intake, are not known.

RESEARCH DESIGN AND METHODS—Eight women (aged 69 years, fasting glucose 3.7–10.3 mmol/l, BMI 22.4–43.9 kg/m²) who had fasted overnight were served a breakfast (450 kcal) with intravenous infusion of saline or synthetic GLP-1 (0.75 pmol · kg^–1 · min^–1), and ß-cell function was evaluated by estimating the relationship between glucose concentration and insulin secretion (calculated by deconvolution of C-peptide data).

RESULTS—GLP-1 markedly augmented insulin secretion, despite lower glucose. Total insulin secretion was 29.7 ± 4.2 nmol/m² with GLP-1 versus 21.0 ± 1.6 nmol/m² with saline (P = 0.048). GLP-1 increased the dose-response relationship between glucose concentration and insulin secretion (70 ± 26 with GLP-1 versus 38 ± 16 pmol insulin · min^-1 · m² · mmol^-1 glucose · l without, P = 0.037) and augmented the potentiation factor that modulates the dose response (2.71 ± 0.42 with GLP-1 versus 0.97 ± 0.17 without, P = 0.005). The potentiation factor correlated to GLP-1 concentration (r = 0.53, P < 0.001); a 10-fold increase in GLP-1 levels produced a twofold increase in the potentiation factor. These effects of GLP-1 did not correlate with fasting glucose levels or BMI.

CONCLUSIONS—Administration of GLP-1 along with ingestion of a meal augments insulin secretion in humans by a dose-dependent potentiation of the dose-response relationship between plasma glucose and insulin secretion.

Abbreviations: GLP-1, glucagon-like peptide 1

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E380 - E384. [Abstract] [Full Text] [PDF]

				A. Mari, W. A. Scherbaum, P. M. Nilsson, G. Lalanne, A. Schweizer, B. E. Dunning, S. Jauffret, and J. E. Foley Characterization of the Influence of Vildagliptin on Model-Assessed -Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 103 - 109. [Abstract] [Full Text] [PDF]

				M. J. Fowler Diabetes Treatment, Part 2: Oral Agents for Glycemic Management Clin. Diabetes, October 1, 2007; 25(4): 131 - 134. [Full Text] [PDF]

				P. M. Jauslin, H. E. Silber, N. Frey, R. Gieschke, U. S. H. Simonsson, K. Jorga, and M. O. Karlsson An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics J. Clin. Pharmacol., October 1, 2007; 47(10): 1244 - 1255. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]

				E. Muscelli, A. Mari, A. Natali, B. D. Astiarraga, S. Camastra, S. Frascerra, J. J. Holst, and E. Ferrannini Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1144 - E1150. [Abstract] [Full Text] [PDF]

				A. Mari, W. M. Sallas, Y. L. He, C. Watson, M. Ligueros-Saylan, B. E. Dunning, C. F. Deacon, J. J. Holst, and J. E. Foley Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed {beta}-Cell Function in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4888 - 4894. [Abstract] [Full Text] [PDF]

				A. Mari, A. Gastaldelli, A. Natali, T. Ostergard, O. Schmitz, and E. Ferrannini Characterization of {beta}-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E541 - E546. [Abstract] [Full Text] [PDF]

				S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]

				B. Ahren, R. Gomis, E. Standl, D. Mills, and A. Schweizer Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes Diabetes Care, December 1, 2004; 27(12): 2874 - 2880. [Abstract] [Full Text] [PDF]

				G. M. Steil, C.-m. Hwu, R. Janowski, F. Hariri, S. Jinagouda, C. Darwin, S. Tadros, K. Rebrin, and M. F. Saad Evaluation of Insulin Sensitivity and {beta}-Cell Function Indexes Obtained From Minimal Model Analysis of a Meal Tolerance Test Diabetes, May 1, 2004; 53(5): 1201 - 1207. [Abstract] [Full Text] [PDF]